{"cluster": 20, "subcluster": 70, "abstract_summ": " SARS-CoV-2 shares 74.5% genome identity with SARS, both exhibiting a similar well conserved structure . Therefore, antibodies produced in COVID-19 and SARS patients should not be that dissimilar . Cross-reactivity was seen in these two test assays with sera from patients from 7 days after onset of symptoms ."}